Ferozsons Laboratories Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0005201014
PKR
379.11
-14.05 (-3.57%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.26

 
2

Healthy long term growth as Operating profit has grown by an annual rate 35.27%

 
3

Positive results in Mar 25

4

With ROE of 7.1, it has a attractive valuation with a 1.3 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 13,039 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.33%

stock-summary
Debt Equity

0.11

stock-summary
Return on Equity

9.19%

stock-summary
Price to Book

1.02

Revenue and Profits:
Net Sales:
6,683 Million
(Quarterly Results - Dec 2025)
Net Profit:
344 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
20.34%
0%
20.34%
6 Months
4.77%
0%
4.77%
1 Year
50.68%
0%
50.68%
2 Years
172.35%
0%
172.35%
3 Years
72.27%
0%
72.27%
4 Years
24.8%
0%
24.8%
5 Years
66.96%
0%
66.96%

Ferozsons Laboratories Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
25.81%
EBIT Growth (5y)
18.40%
EBIT to Interest (avg)
12.26
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
1.11
Tax Ratio
34.23%
Dividend Payout Ratio
22.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.80%
ROE (avg)
9.47%

Valuation key factors

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.48
EV to EBIT
9.57
EV to EBITDA
6.63
EV to Capital Employed
1.42
EV to Sales
1.07
PEG Ratio
0.90
Dividend Yield
1.66%
ROCE (Latest)
14.83%
ROE (Latest)
7.45%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 12.51% vs 31.84% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 6.99% vs 26.09% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,682.60",
          "val2": "5,939.30",
          "chgp": "12.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,056.00",
          "val2": "895.60",
          "chgp": "17.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "98.40",
          "val2": "104.70",
          "chgp": "-6.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "344.40",
          "val2": "321.90",
          "chgp": "6.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "118.60%",
          "val2": "107.30%",
          "chgp": "1.13%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 18.93% vs 38.38% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is 22.00% vs 155.06% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18,856.90",
          "val2": "15,854.80",
          "chgp": "18.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,853.40",
          "val2": "2,108.00",
          "chgp": "35.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "568.50",
          "val2": "670.60",
          "chgp": "-15.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "10.10",
          "val2": "49.70",
          "chgp": "-79.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "921.70",
          "val2": "755.50",
          "chgp": "22.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "101.80%",
          "val2": "99.00%",
          "chgp": "0.28%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
6,682.60
5,939.30
12.51%
Operating Profit (PBDIT) excl Other Income
1,056.00
895.60
17.91%
Interest
98.40
104.70
-6.02%
Exceptional Items
0.00
0.00
Consolidate Net Profit
344.40
321.90
6.99%
Operating Profit Margin (Excl OI)
118.60%
107.30%
1.13%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 12.51% vs 31.84% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 6.99% vs 26.09% in Sep 2025

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
18,856.90
15,854.80
18.93%
Operating Profit (PBDIT) excl Other Income
2,853.40
2,108.00
35.36%
Interest
568.50
670.60
-15.23%
Exceptional Items
10.10
49.70
-79.68%
Consolidate Net Profit
921.70
755.50
22.00%
Operating Profit Margin (Excl OI)
101.80%
99.00%
0.28%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is 18.93% vs 38.38% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is 22.00% vs 155.06% in Jun 2024

stock-summaryCompany CV
About Ferozsons Laboratories Ltd. stock-summary
stock-summary
Ferozsons Laboratories Ltd.
Pharmaceuticals & Biotechnology
Ferozsons Laboratories Limited is a Pakistan-based holding company, which is primarily engaged in importing, manufacturing and sale of pharmaceuticals products. The Company offers a range of branded generics and in-licensed products in the areas of cardiology, oncology, gastroenterology, dermatology and anti-infective markets in the Pakistan. The Company's production capabilities include the manufacturing of tablets, capsules, syrups, suspensions, creams and ointments. Its products include Salazodine EC Tabs, Cimet Tablets and Suspension, Centaurus Tablets, Novapressin, Filgen Injection, Oxaltie Injection, Imuxgen Tablets, Anfogen Injection and Donataxel Injection, among others. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.
Company Coordinates stock-summary
Company Details
197- A ,The Mall , RAWALPINDI None : 46000
Registrar Details